The Effect of Dual Attention in an EMDR Intervention
Launched by UNIVERSIDAD COMPLUTENSE DE MADRID · Oct 26, 2022
Trial Information
Current as of September 04, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The protocol will be developed following the three stages of recovery from trauma: first, focusing on establishing the therapeutic alliance and safety; second, focusing on recounting and re-processing the traumatic event; and third, focusing on reconnecting with others and with life despite the trauma experienced. This study will analyze the differences of type of traumatic processing; 1. using bilateral stimulation, 2. using fixed-point focusing and 3. closing the eyes (only exposure to the traumatic memory, without dual attention).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Those showing a high risk of PTSD (TSQ ≥6 or TSQ ≥4 with clinical criteria) will be further evaluated to determine whether they meet the inclusion criteria. Participants must:
- • 1. Be between the ages of 18 and 65 fluent enough in Spanish language; 2.
- Exclusion Criteria:
- • Present severe active suicidal ideation, or have made a self-injurious attempt during the last month.
- • Present a diagnosis of substance dependence, intellectual disability or severe cognitive dysfunction.
- • Participants with a score greater than or equal to 26 on the BDI-II, the inclusion of the person in the study will be assessed by clinical criteria.
- • Having received EMDR treatment in the last 6 months.
- • Also excluded from the program are those people who cannot guarantee continuity in the therapeutic process.
About Universidad Complutense De Madrid
The Universidad Complutense de Madrid (UCM) is a prestigious academic institution renowned for its commitment to research and innovation in various fields, including health sciences. As a prominent sponsor of clinical trials, UCM leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes. The university fosters collaboration among researchers, clinicians, and industry partners, ensuring the highest standards of ethics and scientific rigor in its clinical research initiatives. UCM's dedication to education and research excellence positions it as a leader in the development of new therapeutic interventions and health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pozuelo De Alarcón, Madrid, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials